Efficacy and safety of low-dose imatinib in an elderly patient with mixed phenotype acute leukemia with t(9;22)(q34;q11.2);BCR-ABL1

Yusuke Okayama; Teruhito Takakuwa; Ippei Otomaru; Mirei Horiuchi; Akiko Miura; Taku Araki; Yotaro Fujitani; Ryosuke Yamamura

doi:10.1002/ccr3.4126

Efficacy and safety of low-dose imatinib in an elderly patient with mixed phenotype acute leukemia with t(9;22)(q34;q11.2);BCR-ABL1

Clin Case Rep. 2021 May 5;9(5):e04126. doi: 10.1002/ccr3.4126. eCollection 2021 May.

Authors

Yusuke Okayama^{1

2}, Teruhito Takakuwa^{1

2}, Ippei Otomaru¹, Mirei Horiuchi¹, Akiko Miura¹, Taku Araki¹, Yotaro Fujitani¹, Ryosuke Yamamura¹

Affiliations

¹ Department of Hematology Osaka Saiseikai Nakatsu Hospital Osaka Japan.
² Department of Hematology Graduate School of Medicine Osaka City University Osaka Japan.

Abstract

Low-dose imatinib with monitoring of drug concentrations in blood may successfully control Philadelphia chromosome-positive mixed phenotype acute leukemia (Ph+MPAL), particularly in elderly patients with comorbidities.

Keywords: Ph+MPAL; dasatinib; elderly; imatinib; interstitial pneumonitis.

Publication types

Case Reports